Background
==========

Stem cells
----------

Adult somatic stem cells are defined as undifferentiated cells with three key properties: long life, multipotency, and the capacity to self-renew.[@b1-sccaa-8-027] However, recent evidence has shown that although their phenotype is tightly defined, these cells are functionally heterogeneous.[@b2-sccaa-8-027] The properties of stem cell self-renewal and survival are controlled by highly conserved embryonic signaling pathways, including the hedgehog (Hh), epithelial-mesenchymal transition, WNT, and Notch signaling pathways, the HOX transcription factors, and the BMI1/polycomb transcriptional regulators.[@b3-sccaa-8-027]

Cancer stem cells
-----------------

There is experimental evidence from a number of malignancies to suggest the presence of a small population of very primitive cells that share many of the properties of somatic stem cells. These cells have been termed cancer stem cells (CSCs).[@b1-sccaa-8-027]

Whilst there is still much to learn in respect of the CSC, various experimental models have shown these cells to be quiescent, resistant to therapy, capable of self-renewal, and the initiation of tumors in secondary transplanted hosts.[@b4-sccaa-8-027] Malignancies with evidence of CSC origin include hematological cancers[@b4-sccaa-8-027],[@b5-sccaa-8-027] and solid tumors including: prostate,[@b6-sccaa-8-027] pancreas,[@b7-sccaa-8-027] lung,[@b8-sccaa-8-027] and certain neurological malignancies.[@b9-sccaa-8-027]

Although the concept of the CSC is largely accepted, the model by which it is capable of generating a tumor, or leukemia, remains contentious.[@b10-sccaa-8-027] The stochastic model argues tumors are biologically homogeneous, with CSC behavior being determined by intrinsic or extrinsic factors; tumor heterogeneity arising because these factors are unpredictable.[@b11-sccaa-8-027] In contrast, the hierarchy model argues CSCs are highly organized in unidirectional cellular hierarchies (the pattern of normal tissue growth). In the hierarchical model, the CSCs are biologically unique.[@b12-sccaa-8-027] The fundamental difference between the models lies in which cell, or cells, are capable of behaving as a CSC with discrimination relying on accurate, well-defined experimental design.[@b13-sccaa-8-027]

The CSC hypothesis is of considerable clinical importance, potentially explaining minimal residual disease, relapse and disease progression, and highlighting the need to target these cells in order to effect a cure.[@b14-sccaa-8-027] CSCs have been shown to be innately less sensitive to treatment, to continually develop genomic and epigenomic changes, and to uniquely interact with the stem cell niche.[@b14-sccaa-8-027],[@b15-sccaa-8-027] The influence each of these factors has on the CSCs treatment-resistant phenotype is however, unclear.

The pathways involved in self-renewal are of intense interest, with many, if not all being implicated in neoplastic proliferation when deregulated.[@b15-sccaa-8-027] It is the behavior of one of these pathways, the Hh signaling pathway, which is the focus of this review.

Hh signaling pathway
--------------------

The Hh signaling pathway was initially discovered in 1980 by Nüsslein-Volhard and Weischaus whilst studying embryonic patterning in the *Drosophila* fruit fly, with absence of the Hh protein giving the *Drosophila* a characteristic "hairy" or "prickly" appearance.[@b16-sccaa-8-027],[@b17-sccaa-8-027] Subsequent work has shown the Hh pathway to be highly conserved across species and vitally important in embryogenesis, performing the function of patterning during the early stages of development through the expansion and contraction of stem cell numbers. In adult organisms, through its ability to affect stem cell behavior in responsive tissues, it is involved in aspects of tissue maintenance and regeneration -- proliferation, apoptosis, chromatin modeling, and self-renewal, acting in concert with other stimuli and the stem cell niche.[@b18-sccaa-8-027]

Canonical signaling
-------------------

Classically, the Hh signaling pathway is believed to be ligand-dependent. Three Hh ligands (Sonic \[SHH\], Indian \[IHH\], and Desert \[DHH\]) have been identified in vertebrates, affecting stem cell behavior in a time- and concentration-dependent manner.[@b19-sccaa-8-027] SHH is widely expressed, particularly during embryogenesis, with SHH deficiency being embryonically lethal.[@b17-sccaa-8-027] IHH is produced in hematopoietic cells, bone, and cartilage,[@b20-sccaa-8-027] whilst DHH is found in the peripheral nervous system and testes.[@b21-sccaa-8-027] Hh ligands are initially synthesized as an inactive 45 kDa precursor, undergoing post-translational modifications to form a 19 kDa amino-terminal active signaling molecule.[@b22-sccaa-8-027] This cholesterol and palmitoyl modification, catalyzed by Hh acyltransferase,[@b23-sccaa-8-027] not only enhances ligand activity but also modifies its diffusion capacity.[@b24-sccaa-8-027] The Hh ligands bind to the 12 trans-membrane receptor protein Patched 1 (PTCH1), causing its internalization and removing its repression of the 7-span trans-membrane protein Smoothened (SMO), allowing pathway activity.[@b25-sccaa-8-027] In vertebrates, activity of the Hh pathway appears intrinsically related to primary immotile cilia; in the absence of ligand, PTCH1 is located within the primary cilia. Following ligand binding, and the internalization of PTCH1, SMO is able to concentrate in the primary cilia where it interacts with the GLI transcription factors shifting the balance toward pathway activation.[@b25-sccaa-8-027] Whilst the intricacies of this interaction remain poorly understood, studies suggest these receptors do not physically interact, rather PTCH1 is thought to regulate SMO through an intermediary, with studies suggesting that oxysterols, including vitamin D3, are involved.[@b26-sccaa-8-027] SMO subsequently causes accumulation of the full length active form of the zinc transcription factors GLI-2 and GLI-3 in the nucleus, and potentiates the activity of other positive regulators of the pathway including serine threonine kinase 36 (STK36) and kinesin family member 7 (KIF7), resulting in transcription of key downstream targets such as *GLI-1* and *PTCH1*, regulators of chromatin formation, cell cycle activity, cell mobility, and apoptosis, eg, bone morphogenetic protein 4, forkhead box protein M1, and *WNT2a*,[@b27-sccaa-8-027] [Figure 1A](#f1-sccaa-8-027){ref-type="fig"}. Of the transcription factors, GLI-1 functions as a positive regulator, GLI-3 a transcriptional repressor, and GLI-2 both a positive and negative transcriptional regulator determined by post-transcriptional and post-translational modifications.[@b28-sccaa-8-027] It is the balance between these transcription factors which determines pathway activity.[@b29-sccaa-8-027]

Alternatively, the Hh ligands can bind to a number of membrane-associated glycoproteins: Patched 2 (PTCH2), Hh-interacting protein (HHIP), and Dispatched (DISP). PTCH2, although structurally similar to PTCH1, has distinct functional properties and notably different tissue distribution, PTCH1 being broadly expressed whilst PTCH2 is primarily restricted to the skin and testes.[@b30-sccaa-8-027],[@b31-sccaa-8-027] HHIP is an endogenous Hh ligand inhibitor, with a binding affinity comparable to PTCH1, preventing pathway activation.[@b32-sccaa-8-027] DISP, a 12 trans-membrane receptor protein, is not involved in Hh ligand synthesis or processing but rather facilitates ligand movement, thereby modulating canonical pathway activity.[@b33-sccaa-8-027]

In the inactive state the transcription factors GLI-2 and GLI-3 are retained in the cytoplasm in a protein complex associated with the inhibitory molecule, suppressor of fused (SUFU)[@b34-sccaa-8-027] and non-specifically phosphorylated by casein kinase (CKI), glycogen synthase 3β (GSK3β), and protein kinase A (PKA). This complex subsequently undergoes E3 ubiquitin-mediated proteolysis by the Skp1-Cullin1-F-box protein (SCF^β-TRCP^) to the truncated repressor form which, on translocating to the nucleus, strongly inhibits the Hh pathway,[@b35-sccaa-8-027] [Figure 1B](#f1-sccaa-8-027){ref-type="fig"}. It is the complex interplay between the active and inactive state of the pathway and the positive and negative feedback loops that maintain the careful balance of Hh signaling in normal tissue.

Non-canonical signaling
-----------------------

The notion of non-canonical signaling has arisen following observations that the pathway response does not always appear to follow the classical canonical signaling paradigm, although the evidence is not conclusive. Three scenarios of non-canonical Hh signaling have been described, [Figure 2](#f2-sccaa-8-027){ref-type="fig"}: direct interaction with components of other pathways, atypical interaction of components, and activity independent of GLI-mediated transcription, defined as Type I (PTCH-dependent) and Type II (SMO-dependent).[@b36-sccaa-8-027] In reality, it is likely the canonical and non-canonical pathways act in parallel.

Downstream targets
------------------

There are numerous downstream targets of the Hh pathway: BCL-2, the ATP-binding cassette transporter family members; the multi-drug resistance protein-1 and components of the epithelial-mesenchymal transition, WNT, and Notch signaling pathways, [Figure 3](#f3-sccaa-8-027){ref-type="fig"}. There is already evidence to show up-regulation and involvement of many of these pathways in chemo-resistance in human malignancies.[@b37-sccaa-8-027],[@b38-sccaa-8-027] Additionally, studies have highlighted several of these downstream targets to be over-expressed in both acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), with expression linked to chemo-resistance and poorer survival.[@b39-sccaa-8-027]

Hh signaling in hematopoiesis
-----------------------------

In vertebrates, hematopoiesis is broadly divided into two major phases, primitive (embryonic) and definitive.[@b40-sccaa-8-027] The Hh signaling pathway has a complex role in both embryonic and adult hematopoiesis. This role appears to be dependent on developmental stage, cell lineage, and whether the hematopoietic system is under regenerative pressure.[@b27-sccaa-8-027],[@b41-sccaa-8-027] Whilst evidence has shown it to be vital for early hematopoietic development,[@b20-sccaa-8-027] there remains controversy over its role in normal hematopoiesis in adult organisms,[@b41-sccaa-8-027]--[@b43-sccaa-8-027] although some of this may be explained by experimental method. Interestingly, recent early phase clinical trials looking at SMO inhibition have shown little or no hematopoietic toxicity potentially indicating Hh signaling may be dispensable in certain situations.[@b44-sccaa-8-027] Importantly, abrogation of canonical Hh signaling by knockout of SMO does not adversely affect steady-state normal hematopoiesis.[@b42-sccaa-8-027],[@b45-sccaa-8-027]

Hh signaling in malignancy
--------------------------

Crucially, abnormal Hh signaling has been associated with diverse human malignancies including basal cell carcinoma,[@b46-sccaa-8-027] medulloblastoma,[@b47-sccaa-8-027] pancreatic,[@b48-sccaa-8-027] and lung cancer.[@b49-sccaa-8-027] Interestingly, data suggest different mechanisms of action in the various tumor environments. Constitutive pathway activation through loss-of-function mutations,[@b46-sccaa-8-027] epigenetic modifications,[@b50-sccaa-8-027] or reduced expression of the negative regulators PTCH, HHIP, and SUFU[@b51-sccaa-8-027] or gain-of-function mutations and epigenetic changes[@b52-sccaa-8-027] in the positive regulator SMO have been observed in a number of solid malignancies.[@b53-sccaa-8-027] To date, no mutations have been identified in hematological malignancies; however, epigenetic modifications have been observed in a cohort of pediatric AML patients, correlating with disease status.[@b54-sccaa-8-027] Ligand-dependent canonical pathway activation involves autocrine or paracrine Hh signaling.[@b55-sccaa-8-027] Autocrine Hh signaling has been identified in multiple myeloma (MM),[@b56-sccaa-8-027] prostate,[@b57-sccaa-8-027] and lung cancer.[@b58-sccaa-8-027] Paracrine Hh signaling has been observed in lymphoma,[@b59-sccaa-8-027] colon, and pancreatic cancer.[@b60-sccaa-8-027]

Hh signaling in myeloid malignancies
------------------------------------

In myeloid malignancies, Hh signaling has been found to be vital in the maintenance and expansion of the CSC or "leukemic stem cell" (LSC), either as a survival and proliferation signal or through direction of the LSC fate.[@b27-sccaa-8-027],[@b61-sccaa-8-027]--[@b64-sccaa-8-027]

CML is a clonal myeloproliferative disease driven by the Philadelphia chromosome which encodes the constitutively active BCR-ABL tyrosine kinase. For CML to develop, this mutation must originate in a multi-potent hematopoietic stem cell (HSC), producing the leukemia-initiating cell or LSC.[@b65-sccaa-8-027] Acquisition of BCR-ABL by an HSC results in a number of functional changes, including increased proliferation, differentiation block, inhibition of apoptosis, and altered cell adhesion and stromal interactions, producing the clinical phenotype of CML.[@b66-sccaa-8-027]

The development of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, with the majority of patients now achieving long-term survival with a good quality of life.[@b67-sccaa-8-027] TKI therapy, however, is not without side effects, nor is it effective in all patients; TKI resistance and disease persistence despite TKI therapy remain ongoing issues. Persistent disease is believed to be due to lack of dependence on BCR-ABL signaling for survival and TKI resistance in CML stem cells.[@b68-sccaa-8-027]

Hh signaling appears to be intimately involved in the persistence and expansion of these CML stem cells.[@b35-sccaa-8-027],[@b43-sccaa-8-027],[@b61-sccaa-8-027] Two different *SMO*-deficient murine models have shown supporting results -- reduced incidence of leukemia in primary and secondary transplant recipients and a prolonged latency in primary transplantation.[@b43-sccaa-8-027],[@b61-sccaa-8-027] Additionally, these groups demonstrated improved survival, with an accompanying reduction in the LSC population following treatment with the SMO antagonist cyclopamine; combination therapy with a TKI and cyclopamine resulting in the largest reduction in LSCs in vitro and in vivo. These findings are supported by studies using clinical grade SMO inhibitors alone, and combined with TKIs, showing an improved survival, with a reduced incidence of leukemia in secondary transplant recipients and a marked reduction in measures of self-renewal.[@b69-sccaa-8-027] Supporting work in NOD *scid* gamma mice, looking at molecular targets, has shown targeting the Hh pathway with dasatinib and GDC-0449 resulted in reduced expression of GLI-1, GLI-2, BCL-2, and Cyclin D2, and increased expression of p21, pATM, pChk2, and γH2AX.[@b70-sccaa-8-027] Interestingly, low *PTCH1* expression has been found to be an independent predictor of imatinib failure and reduced overall survival.[@b71-sccaa-8-027]

AML is an extremely heterogeneous clonal disorder. Whilst there is clear evidence to support the CSC theory in AML,[@b4-sccaa-8-027],[@b72-sccaa-8-027] recent work has suggested the LSC population is phenotypically variable, and may not be confined to a single clonal subpopulation. Further, whether this LSC arises following progenitor cell acquisition of abnormal self-renewal potential or from an HSC remains unclear.[@b4-sccaa-8-027],[@b5-sccaa-8-027],[@b72-sccaa-8-027]

There is increasing evidence showing the Hh pathway is deregulated in AML. Leukemic cell lines and primary AML cells express components of the Hh pathway, *SHH* and *GLI-1*.[@b73-sccaa-8-027] *GLI-1* expression correlating with cytogenetic risk, inferior event-free survival and a reduced overall survival, with *GLI-1* conferring drug resistance through UGT1A-dependent glucuronidation.[@b74-sccaa-8-027] Further, high GLI-1 expression predicts poor remission status and reduced overall survival in secondary AML.[@b75-sccaa-8-027] *GLI-2* has been shown to be a negative prognostic indicator in a number of microarrays. Additionally, aberrant Hh signaling has been linked to drug resistance with inhibition of the pathway restoring chemosensitivity in AML.[@b36-sccaa-8-027],[@b62-sccaa-8-027] Further, pathway inhibition with PF-04449913 sensitized AML cell lines and primary cells to the standard chemotherapy agent cytarabine; additional inhibition of *SMO* modulated cell cycle and self-renewal signaling.[@b76-sccaa-8-027] In pediatric AML the hypo- and hypermethylation of pathway promoters were highly associated with AML diagnosis and relapse.[@b54-sccaa-8-027] The complex interplay between the intrinsic and extrinsic signals governing LSC behavior may, however, mean targeting a single pathway, such as the Hh pathway, is not sufficient to eradicate these CSCs. For example, in an *MLL-AF9*-mediated murine model of myeloid leukemia Hh signaling was completely dispensable for the development of acute leukemia.[@b42-sccaa-8-027],[@b45-sccaa-8-027]

The role of the Hh pathway in myelodysplastic syndrome (MDS) is not so well understood. However, there is increasing evidence to show it is deregulated. Analysis of primary MDS samples found overexpression of SHH, DHH, *PTCH1*, and *SMO*.[@b77-sccaa-8-027] Further, there was a correlation between ligand expression and the progenitor/stem cell marker c-KIT.[@b77-sccaa-8-027]

Interestingly, work has shown the Hh pathway to act on the microenvironmental stromal cells, thereby regulating HSC behavior,[@b64-sccaa-8-027] with the Hh ligands acting in an autocrine and/or paracrine manner.[@b59-sccaa-8-027],[@b62-sccaa-8-027],[@b78-sccaa-8-027] Moreover, *HHIP* was highly expressed in primary stromal cells, but not in primary peripheral blood, bone marrow, or cord blood CD34+ selected cells, with stromal *HHIP* expression suppressing leukemic cell proliferation.[@b79-sccaa-8-027] Further, studies have demonstrated *HHIP* expression in AML and MDS-derived bone marrow stromal cells to be markedly reduced, with these cells supporting the proliferation of leukemic cells; pretreatment with azacitidine increased stromal cell *HHIP* expression, with a parallel reduction in leukemic cell proliferation in co-culture.[@b79-sccaa-8-027]

Myeloproliferative neoplasms is a term encompassing several BCR-ABL-negative neoplasms -- myelofibrosis (MF), polycythemia vera, and essential thrombocythemia -- characterized by stem cell-derived clonal myeloproliferation and the Janus kinase 2 (JAK2V617F)[@b80-sccaa-8-027] or Calreticulin mutation.[@b81-sccaa-8-027] There are limited data available on the Hh pathway in these malignancies. *GLI-1* and *PTCH1* are increased 20--100-fold in primary myeloproliferative neoplasms samples, with pathway activity demonstrated in a murine bone marrow transplant model of MF using a GLI-luciferase reporter system. Combining the SMO antagonist LDE225 with INC424, a JAK1/2 dual kinase inhibitor, in this murine model saw a reduction in mutant allele burden and an improved clinical phenotype.[@b82-sccaa-8-027] Another murine model of MF (Gata1^low^) has shown alterations in the Hh pathway at the gene level in the bone marrow and spleen, components of the Hh pathway coordinating with TGFβ, p53, and mTOR-related genes to produce the biological phenotype of MF.[@b83-sccaa-8-027] However, a recent Phase II clinical trial using IPI-926 in MF saw the majority of patients taken off therapy due to side effects or no response.[@b84-sccaa-8-027] How the Hh inhibitors work in combination with other novel drugs remains to be fully ascertained.

Hh signaling in lymphoid disorders
----------------------------------

Hh signaling is vital for normal B- and T-cell development; with Hh ligands, produced by either the bone marrow or lymphoid organ microenvironment, determining lymphoid cell behavior.[@b63-sccaa-8-027]

B-cell disorders
----------------

B-cell acute lymphoblastic leukemia (B-ALL) is thought to develop from the malignant transformation of immature hematopoietic progenitor cells. Unlike AML, in which the CSC hypothesis was first demonstrated and is widely accepted, the B-ALL LSC has yet to be isolated or characterized,[@b85-sccaa-8-027] blasts from all stages of maturation being able to reconstitute and establish a leukemic phenotype in vivo.[@b86-sccaa-8-027] Interestingly however, up-regulation of components of the Hh pathway has been observed in precursor B-ALL,[@b87-sccaa-8-027] SMO inhibition reducing in vitro and in vivo measures of self-renewal.[@b88-sccaa-8-027]

B-cell chronic lymphocytic leukemia (B-CLL) is a clonal disorder of mature, differentiated lymphocytes. Although not a CSC disease, both components of the Hh pathway (*GLI-1, GLI-2*, and *SUFU*) and key downstream targets (*BCL-2, BCL-XL*) are increased, and importantly correlate with clinical outcome.[@b89-sccaa-8-027] Expression of *BCL-2* is increased in the presence of active Hh signaling and down-regulated upon inhibition of the pathway.[@b59-sccaa-8-027] Further, cyclopamine increased apoptosis of B-CLL cells in vitro, in stromal co-culture conditions and in combination with fludarabine.[@b59-sccaa-8-027],[@b89-sccaa-8-027] Gene expression of components of the Hh pathway is extremely variable in CLL patients, with expression correlating with response to SMO inhibition. Sixty percent of treated patient samples responded to at least one SMO antagonist; likelihood of response correlating with elevated *GLI-1* and *PTCH1* expression and the presence of trisomy 12 (a poor prognostic indicator). This work also showed evidence of autocrine DHH signaling, potentially enabling non-canonical signaling in B-CLL cells.[@b90-sccaa-8-027] In contrast, another study found *PTCH1, SMO*, and *GLI-1* to be reduced in primary CLL samples, although there was considerable heterogeneity -- about 25% showing high transcript levels compared to normal B-lymphocytes. GANT61, a direct GLI inhibitor, induced apoptosis in a time- and concentration-dependent manner in association with STAT3 phosphorylation.[@b91-sccaa-8-027] A further study found *SMO* and *GLI-1* to be significantly down-regulated in B-CLL cells compared to normal B cells.[@b92-sccaa-8-027] Moreover, whilst cyclopamine and knockdown of *SMO* had only minor specific effects on B-CLL cell survival in vitro, GANT61 caused significant apoptosis in B-CLL cells but not normal B cells.[@b92-sccaa-8-027] Combined treatment with GANT61 and fludarabine causing increased apoptosis compared to either agent alone. Interestingly however, whilst CLL viability improved in the presence of the stromal cell lines HS-5 and M210-B4, known to produce Hh ligands,[@b59-sccaa-8-027],[@b92-sccaa-8-027] the same effect was not achieved with soluble SHH indicating other factors are involved. So, whilst these results support previous reports of Hh pathway activity in CLL, they would support redundancy of canonical Hh signaling in vitro.

The term lymphoma encompasses a broad spectrum of diseases from the relatively indolent to the aggressive and rapidly fatal; each has a complex and heterogeneous pathogenesis. Broadly there are two categories, Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Components of the Hh pathway and key downstream targets (BCL-2 and BCL-XL) are expressed in a variety of NHL cell lines and primary tissue,[@b59-sccaa-8-027],[@b93-sccaa-8-027] with expression of the downstream targets being influenced by the Hh pathway.

Whilst an *E*μ-*myc* murine model of Burkitt's lymphoma, an extremely aggressive form of NHL, demonstrated the importance of stromal co-culture for lymphoma cell survival and expansion, stroma could be replaced with soluble SHH or IHH.[@b59-sccaa-8-027] Moreover, Burkitt's cells underwent apoptosis in the absence of Hh signaling both in vitro and in vivo.

In diffuse large B-cell lymphoma (DLBCL), an aggressive form of NHL, response to Hh signaling is dependent on subtype, predominantly inducing cell cycle arrest in germinal center B-cell type, and apoptosis in the activated B-cell type.[@b93-sccaa-8-027] In addition to responding to the Hh ligands, these DLBCL cells were also shown to synthesize and secrete Hh ligands, supporting a role for autocrine signaling.[@b94-sccaa-8-027] Pharmacological and silencing techniques have shown expression of the AKT genes to be modulated by the Hh pathway in DLBCL at the transcriptional level,[@b95-sccaa-8-027] with another study showing that the Hh pathway activates the NF-kβ pathway.[@b96-sccaa-8-027]

In another form of aggressive NHL, mantle cell lymphoma, a therapy-resistant murine model showed up- regulation of the *GLI* transcription factors at the gene level,[@b97-sccaa-8-027] confirming previous work showing the GLI transcription factors to be over-expressed in mantle cell lymphoma, both in cell lines and primary lymphoma cells, compared to normal B cells.[@b98-sccaa-8-027] Further, targeting the GLI transcription factors with antisense oligonucleotides down-regulated *BCL-2* and *Cyclin D1* resulting in decreased proliferation and increased susceptibility to chemotherapy.[@b98-sccaa-8-027]

Whilst these represent high grade forms of NHL, the Hh pathway has also been found to be deregulated and amenable to therapeutic intervention in low-grade lymphomas. In Waldenstrom's macroglobulinemia, a characteristically indolent form of lymphoma secreting immunoglobulin M (IgM), GLI-2 has been found to influence IgM levels. Further, GANT61 resulted in a significant reduction in IgM secretion across a number of Waldenstrom's macroglobulinemia cell lines potentially through the interleukin-6 receptor; this effect was not seen with cyclopamine.[@b99-sccaa-8-027]

In classical HL, whilst the Hh ligands and GLI transcription factors *GLI-1* and *-2* were expressed at a relatively low level, *GLI-3* was highly expressed in all cell lines. Furthermore, immunohistochemistry for GLI-3 showed strong, uniform nuclear expression in virtually all Hodgkin/Reed-Stenberg cells whilst expression was variable in nodular lymphocyte predominant HL and NHL.[@b100-sccaa-8-027] Interestingly GLI-3 in thymic stromal cells has been shown to regulate T-cell selection and thymocyte differentiation;[@b101-sccaa-8-027] whether it is responsible for a similar role in HL remains to be determined.

MM is a CSC disorder, arising from the proliferation of a clonal population of plasma cells, and associated with the production of monoclonal immunoglobulin. Despite a variety of therapeutic approaches MM is incurable with a relapsing natural history; it is the MM CSC which is believed to be resistant to standard therapies, including lenalidomide, bortezomib, dexamethasone, and cyclophosphamide.

In MM, Hh pathway activity has been implicated in the maintenance and differentiation of the CSC.[@b56-sccaa-8-027],[@b78-sccaa-8-027] Pathway inhibition, with cyclopamine, or neutralization, using the monoclonal antibody 5E1, resulted in contraction of the CSC compartment, whereas exogenous Hh ligand caused expansion.[@b78-sccaa-8-027] In addition, using LDE225 to target canonical signaling, and Forskolin a GLI-1 modulating compound, thereby bypassing PTCH1 and SMO and targeting non-canonical signaling, investigators have shown both mechanisms are amenable to therapeutic intervention in vitro in cell lines and patient samples.[@b56-sccaa-8-027] Supporting evidence, using LDE225, confirmed differentiation was significantly induced and de-differentiation blocked in both cell lines and primary cells in vitro.[@b102-sccaa-8-027] Moreover, there was a marked discrepancy in Hh pathway component expression, activity, and cyclopamine sensitivity between the stem cell and differentiated cell compartments.[@b78-sccaa-8-027] Interestingly, Hh pathway gene expression was significantly altered in vivo suggesting the cell microenvironment markedly affects expression of Hh pathway components.[@b78-sccaa-8-027]

T-cell disorders
----------------

T-cell disorders, characterized by the abnormal proliferation of T-cell precursors, are generally aggressive, and far rarer than B-cell disorders. Interestingly, in comparison to B-ALL and B-cell lymphomas there are significant similarities between T-ALL and T-cell lymphomas; many arguing these entities are variations of the same disease, the two conditions often being treated in the same way.[@b103-sccaa-8-027]

The Hh pathway has been shown to be important in T-cell development;[@b104-sccaa-8-027] it has also been implicated in the etiology of T-cell malignancies. In ALK^+^ anaplastic large cell lymphoma cell lines and primary tissue, *SHH* was amplified. In addition, GLI-1 expression at both the gene and protein level was increased; both *SHH* and *GLI1* expression being influenced by the PI3K/AKT pathway although the mechanism remains unclear.[@b105-sccaa-8-027] Supporting the importance of these components in cell survival, inhibition of SHH signaling with cyclopamine or silencing *GLI-1* with ribonucleic acid interference resulted in cell cycle arrest and apoptosis.[@b105-sccaa-8-027]

Epigenetic modifications of the Hh pathway
------------------------------------------

Epigenetic modifications are stable, heritable alterations in gene expression caused without a change in coding DNA but rather DNA methylation and histone modification.[@b106-sccaa-8-027] The bromodomain and extra-terminal domain (BET) protein family, responsible for reading differentially acetylated histones and thereby communicating changes in transcription potential, comprises four distinct genes, *BRD2, -3,* and *-4* which are ubiquitously expressed and *BRDT* which is restricted to the testes. Importantly, there is increasing evidence to support the epigenetic modification of components of the Hh pathway. Work has predominantly focused on neural tissue and medulloblastoma, finding GLI-1 and GLI-2, but not GLI-3, to be acetylated, with a careful regulatory balance controlling GLI acetylation, and thereby transcriptional activity.[@b107-sccaa-8-027] Transcriptional activity occurs through histone deacetylation, whilst the binding of REN^KCTD11^, an endogenous histone deacetylase inhibitor, to SCF^(Β-TrCP)^3-like E3 ubiquitin ligase complex, promotes GLI acetylation inhibiting transcription.[@b108-sccaa-8-027] Recent work has shown BET proteins to further modulate GLI transcription and thereby pathway activity.[@b109-sccaa-8-027] Targeting BRD4 with JQ1, a small-molecule bromodomain inhibitor, preventing BRD4 acetyl-lysine binding resulted in a global down-regulation of GLI associated genes in both patient and genetically engineered mouse model-derived Hh-driven tumors.[@b109-sccaa-8-027] It remains to be seen whether this will translate into clinical practice. Further, how epigenetic modification of other components of the pathway will affect Hh antagonism in clinical practice and whether these too will be amenable to manipulation remains to be investigated.

Targeting the Hh pathway in hematological malignancies
------------------------------------------------------

There is increasing evidence to support the role of the Hh signaling pathway in hematological malignancies, with components representing viable therapeutic targets, making it a very attractive potential treatment strategy. Further, from a drug development perspective, inhibition of SMO and GLI-1 can be readily achieved, [Table 1](#t1-sccaa-8-027){ref-type="table"}.

The rationale for Hh inhibition in hematological malignancies is to target the LSC population, eradicating these therapy resistant cells, potentially affecting a cure. However, whilst there is evidence that the Hh pathway is important for LSC maintenance and expansion in CML and MM, its role in other diseases such as AML, MF, CLL, and lymphoma appears more complex, representing a delicate balance between the diseased cells and the stromal microenvironment. Whether Hh antagonism will be therapeutically useful in hematologic malignancies not only depends on its ability to target the diseased cells but also on the anticipated level of toxicity, both hematologic and systemic. To date, there appears to be little hematologic toxicity reported, particularly in solid tumor studies.[@b130-sccaa-8-027]

Whilst experimental data suggest Hh antagonism may address the persistence of CSC and the protective effect of the tumor microenvironment in both myeloid and lymphoid malignancies, clinical trials are only in the early stages, [Table 2](#t2-sccaa-8-027){ref-type="table"}. Interestingly, it is only the SMO antagonists which are currently being trialed clinically. Excitingly however, several of these clinical grade SMO inhibitors are now in Phase II trial; with a number of Phase III trials in solid tumors and the licensing of vismodegib for use in basal cell carcinoma in 2012 hinting these early results could translate into clinical practice.

In hematological malignancies, results of a Phase Ia study using PF-04449913 in refractory, resistant, or intolerant myeloid malignancies were presented in 2011.[@b131-sccaa-8-027] Thirty-two patients were enrolled, with early indications of efficacy seen across all diseases.[@b131-sccaa-8-027] Notably, one patient with AML achieved a complete remission albeit with incomplete blood recovery and five had a \>50% reduction in bone marrow blast counts. Additionally, one patient with MF achieved a \>50% reduction in extramedullary disease and five attained stable disease. Results of the current Phase II trials are eagerly awaited.

Conclusion
==========

Deregulated expression of components of the Hh signaling pathway is found throughout the huge range of hematological malignancies; the pathway appearing to either determine CSC behavior directly or indirectly via the stromal microenvironment.

As our knowledge and understanding of the Hh and other conserved embryonic pathways in hematologic malignancies increases, our ability to manipulate and potentially use these as therapeutic targets can only increase. Further, the sheer number of compounds coming onto the market, targeting both canonical and non-canonical mechanisms and the array of clinical trials, makes this an exciting time looking to tailor therapy and minimize treatment-related side effects.
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![Canonical Hedgehog (Hh) signaling.\
**Notes:** (**A**) In the inactive state the transcription factors GLI-2 and GLI-3 are non-specifically phosphorylated by casein kinase (CKI), glycogen synthase 3β (GSK3β) and protein kinase A (PKA) and retained in the cytoplasm in a protein complex associated with the inhibitory molecule suppressor of fused (SUFU). This complex undergoes E3 ubiquitin mediated proteolysis to the truncated repressor form which, on translocating to the nucleus, strongly inhibits the Hh pathway. (**B**) The Hh pathway is activated by the binding of Hh ligands (sonic \[SHH\], Indian \[IHH\] or desert \[DHH\]) to the receptor Patched1 (PTCH1), causing its internalisation and removing repression of Smoothened (SMO). SMO causes accumulation of the active from of GLI-2 and GLI-3 in the nucleus, and potentiates the activity of other positive regulators of the pathway resulting in transcription of key downstream targets and regulators of chromatin formation, cell cycle activity, cell mobility and apoptosis.\
**Abbreviations:** DISP, Dispatched; KIF 7, Kinesin family member 7; EMT, epithelial mesenchymaltransition; SCF^(β-TRCP)^, Skp1-Cullin1-F-Box.](sccaa-8-027Fig1){#f1-sccaa-8-027}

![Non-canonical Hh signaling.\
**Note:** The Hh pathway can be activated directly through PTCH1 or SMO, or via alternative pathways including the PI3K/AKT and RAS/RAF/MEK/ERK signaling cascades.\
**Abbreviations:** Hh, hedgehog; EMT, epithelial-mesenchymal transition; PTCH1, Patched 1; SMO, Smoothened.](sccaa-8-027Fig2){#f2-sccaa-8-027}

![Targets of the Hh signaling pathway.\
**Abbreviations:** Hh, hedgehog; EMT, epithelial-mesenchymal transition.](sccaa-8-027Fig3){#f3-sccaa-8-027}

###### 

Hedgehog inhibitors

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Product name                                                         Mechanism of inhibition
  -------------------------------------------------------------------- ------------------------------------------------------------------------------
  **Research**                                                         

  Arsenic trioxide                                                     Inhibits GLI proteins\
                                                                       Degradation of PML-RARA fusion protein[@b110-sccaa-8-027]

  AY9944                                                               Inhibits hedgehog pathway, possibly by several mechanisms[@b111-sccaa-8-027]

  Ciliobrevin A                                                        Hedgehog pathway antagonist, inhibits ciliogenesis[@b112-sccaa-8-027]

  Cyclopamine                                                          Smoothened antagonist[@b113-sccaa-8-027]

  GANT58                                                               Inhibitor of GLI-1-induced transcription[@b114-sccaa-8-027]

  GANT61                                                               Inhibitor of GLI-1-and GLI-2-induced transcription[@b114-sccaa-8-027]

  HPI-1                                                                Inhibits hedgehog pathway[@b115-sccaa-8-027]

  Itraconazole                                                         Smoothened antagonist\
                                                                       Triazole antifungal[@b116-sccaa-8-027]

  Jervine                                                              Inhibits hedgehog pathway[@b111-sccaa-8-027]

  JK184                                                                Prevents GLI transcriptional activity[@b117-sccaa-8-027]

  MRT-10                                                               Smoothened antagonist[@b118-sccaa-8-027]

  PF-5274857                                                           Smoothened antagonist[@b119-sccaa-8-027]

  Robotnikinin                                                         Inhibits SHH[@b120-sccaa-8-027]

  RU-SKI 43 hydrochloride                                              Hedgehog acetyltransferase inhibitor[@b121-sccaa-8-027]

  SANT                                                                 Smoothened antagonist[@b122-sccaa-8-027]

  SMANT hydrochloride                                                  Inhibits SHH-induced accumulation of SMO[@b123-sccaa-8-027]

  U18666A                                                              Inhibits hedgehog pathway[@b124-sccaa-8-027]

  **Clinical grade**                                                   

  BMS-833923 (Bristol-Myers Squibb; New York City, NY, USA)            Smoothened antagonist[@b125-sccaa-8-027]

  GDC-0449 (vismodegib) (Genentech; San Francisco, CA, USA)            Specific hedgehog inhibitor\
                                                                       FDA approval January 30, 2012[@b126-sccaa-8-027]

  IPI-926 (saridegib) (Infinity Pharmaceuticals; Cambridge, MA, USA)   Cyclopamine analog[@b127-sccaa-8-027]

  LDE225 (erismodegib) (Novartis; Basel, Switzerland)                  Smoothened antagonist[@b128-sccaa-8-027]

  PF-04449913 (Pfizer; New York City, NY, USA)                         Smoothened antagonist[@b129-sccaa-8-027]

  TAK-441(Millennium Pharmaceuticals; London, UK)                      Smoothened antagonist[@b130-sccaa-8-027]
  ---------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** FDA, US Food and Drug Administration; SHH, Sonic hedgehog; SMO, Smoothened.

###### 

Clinical trials involving hedgehog inhibitors

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                                                                                                                                             Condition                                                      Phase         Clinical trial number        Status
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- ------------- ---------------------------- -----------------------
  Dasatinib combined with BMS-833923 (Bristol-Myers Squibb; New York City, NY, USA)                                                                                                CML with resistance/suboptimal response to a prior TKI         Phase I/II    NCT01218477                  Completed

  Dasatinib alone or in combination with BMS-833923 (Bristol-Myers Squibb)                                                                                                         Newly diagnosed Ph+ CP CML                                     Phase II      2011-000083-10               Completed

  GDC-0449 (vismodegib) (Genentech; San Francisco, CA, USA)                                                                                                                        Refractory or relapsed B-cell lymphoma or CLL                  Phase II      NCT01944943                  Recruiting

  GDC-0449 (vismodegib) after autologous SCT                                                                                                                                       Multiple myeloma                                               Phase Ib      NCT01330173                  Active not recruiting

  Ribavirin, GDC-0449 (Roche; Basel, Switzerland) (vismodegib) and/or azacitidine (Celgene; Summit, NJ, USA)                                                                       Adult AML                                                      Phase II      NCT02073838                  Not yet recruiting

  IPI-926 (Infinity Pharmaceuticals; Cambridge, MA, USA)                                                                                                                           Primary/secondary MF                                           Phase II      NCT01371617                  Completed

  Ruxolitinib (INC424) (Incyte Pharmaceuticals; Alapocas, DE and Novartis; Basel, Switzerland) LDE225 (Novartis; Basel, Switzerland)                                               MF                                                             Phase Ib/II   NCRN515                      Recruiting

  Azacitidine and LDE225                                                                                                                                                           Myeloid malignancies                                           Phase I/Ib    NCT02129101                  Recruiting

  PF-04449913 (Pfizer; New York City, NY, USA)                                                                                                                                     Hematologic malignancies                                       Phase I       NCT00953758                  Completed

  PF-04449913 alone or in combination with LDAC (Pfizer; New York City, NY, USA), daunorubicin (Zentiva; Prague) or cytarabine (Pfizer; New York City, NY, USA)                    Japanese patients with: AML\                                   Phase I       NCT02038777                  Recruiting
                                                                                                                                                                                   MDS                                                                                                       

  PF-04449913 in combination with intensive chemotherapy, LDAC or cytarabine or decitabine (Bristol-Myers Squibb) or daunorubicin (Bristol-Myers Squibb; New York City, NY, USA)   AML and high-risk MDS                                          Phase I/II    NCT01546038/2012-000684-24   Recruiting

  PF-04449913                                                                                                                                                                      Acute leukemia with high risk of post-allogeneic SCT relapse   Phase II      NCT01841333                  Recruiting

  PF-04449913                                                                                                                                                                      MDS\                                                           Phase II      NCT01842646                  Recruiting
                                                                                                                                                                                   CMML                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; CP, chronic phase; MF, myelofibrosis; MPN, myeloproliferative neoplasms; CML, chronic myeloid leukemia; CLL, chromic lymphocytic leukemia; SCT, stem cell transplant; Ph+, Philadelphia chromosome positive (BCR-ABL); TKI, tyrosine kinase inhibitor; LDAC, low dose cytarabine.
